Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Post Earnings of -$0.76 Per Share

Share on StockTwits

Brokerages predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report earnings per share (EPS) of ($0.76) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.80) to ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 375%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 11th.

On average, analysts expect that Lexicon Pharmaceuticals will report full year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.78 to $0.87. For the next year, analysts forecast that the firm will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.80. The business had revenue of $294.45 million for the quarter, compared to analysts’ expectations of $12.00 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business’s revenue was up 4124.5% on a year-over-year basis. During the same period last year, the business earned ($0.26) EPS.

A number of research analysts recently weighed in on LXRX shares. Wedbush reissued a “buy” rating and set a $17.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $3.00 to $4.00 in a report on Friday, November 8th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 27th. Finally, Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $6.45.

Shares of NASDAQ LXRX traded down $0.52 during trading on Wednesday, hitting $3.01. The stock had a trading volume of 83,326 shares, compared to its average volume of 1,170,697. The firm has a fifty day moving average of $3.62 and a two-hundred day moving average of $3.95. The company has a market capitalization of $375.14 million, a PE ratio of -2.64 and a beta of 1.00. The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $8.40.

In related news, Director Christopher J. Sobecki purchased 99,249 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were acquired at an average cost of $2.41 per share, with a total value of $239,190.09. Following the purchase, the director now directly owns 13,645 shares of the company’s stock, valued at $32,884.45. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Sobecki acquired 25,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was acquired at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the transaction, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Insiders purchased 178,749 shares of company stock worth $474,560 over the last ninety days. 6.40% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in LXRX. Commonwealth Equity Services LLC grew its stake in shares of Lexicon Pharmaceuticals by 40.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 4,746 shares during the last quarter. Quantitative Systematic Strategies LLC raised its position in shares of Lexicon Pharmaceuticals by 67.2% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 8,302 shares during the last quarter. State Street Corp boosted its stake in Lexicon Pharmaceuticals by 1.5% in the 3rd quarter. State Street Corp now owns 952,606 shares of the biopharmaceutical company’s stock worth $2,867,000 after purchasing an additional 13,654 shares in the last quarter. Swiss National Bank increased its stake in Lexicon Pharmaceuticals by 18.3% during the 2nd quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock valued at $557,000 after purchasing an additional 13,700 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at about $92,000. 96.27% of the stock is owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What is Liquidity?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.